Indication and
Limitations of Use:

Parsabiv® (etelcalcetide) is indicated for the treatment of secondary hyperparathyroidism (HPT) in adult patients with chronic kidney disease (CKD) on hemodialysis.

Parsabiv® has not been studied in adult patients with parathyroid carcinoma, primary
hyperparathyroidism, or with CKD who are not on hemodialysis and is not recommended for use in these populations.

THE RESOURCES YOU NEED,
ALL IN ONE PLACE

Ordering Portal
Ordering Portal

Order Parsabiv® resources and ship
directly to your practice

Connect With Us
Connect With Us

Ready to learn more?
Let's get the conversation started.

Video Resources

Nephrologist: Dr Sprague

Learn more about the first and only IV calcimimetic, including mechanism of action.1

Dr. Batarsé: Parsabiv® in the Treatment of sHPT (PCS)

Watch nephrologist Dr. Batarsé talk about the role of Parsabiv® in the treatment of sHPT.

Parsabiv® in Practice

Nephrology professionals discuss the ins and outs of using Parsabiv® in the clinic.

Setting Clinical Expectations for sHPT Patients Prescribed Parsabiv®

Dr. Batarsé gets into great detail on how Parsabiv® performed in the placebo-controlled studies.

Administration, Storage, & Handling

Watch this video, geared specifically toward nurses, on how to store and administer Parsabiv®.

Downloadable Resources

Prescribing Information

Prescribing Information

Storage, Handing, and Adminstration Guide

Storage, Handing, and Administration Guide

A quick reference on how to use Parsabiv® (etelcalcetide).

Dosing Pocket Guide

Dosing Pocket Guide

Helpful Parsabiv® (etelcalcetide) dosing information to keep by your side.

Clinical Reference Guide

Clinical Reference Guide

Important clinical data to share with your colleagues.

Sample Letter of Medical Necessity

Sample Letter of Medical Necessity

Important information that may be needed for a patient’s treatment justification.

Prescribing Information

Patient Education Tear Sheet

A tool that helps compile the necessary data on your patient’s sHPT for a new path forward with Parsabiv®.

Important Safety Information for Parsabiv®

Contraindication: Parsabiv® (etelcalcetide) is contraindicated in patients with known hypersensitivity to etelcalcetide or any of its excipients. Hypersensitivity reactions, including face edema and anaphylactic reaction, have occurred.

Hypocalcemia: Parsabiv® lowers serum calcium and can lead to hypocalcemia, sometimes severe. Significant lowering of serum calcium can cause QT interval prolongation and ventricular arrhythmia. Patients with conditions that predispose to QT interval prolongation and ventricular arrhythmia may be at increased risk for QT interval prolongation and ventricular arrhythmias if they develop hypocalcemia due to Parsabiv®. Closely monitor corrected serum calcium and QT interval in patients at risk on Parsabiv®.

Significant reductions in corrected serum calcium may lower the threshold for seizures. Patients with a history of seizure disorder may be at increased risk for seizures if they develop hypocalcemia due to Parsabiv®. Monitor corrected serum calcium in patients with seizure disorders on Parsabiv®.

Concurrent administration of Parsabiv® with another oral calcimimetic could result in severe, life-threatening hypocalcemia. Patients switching from cinacalcet to Parsabiv® should discontinue cinacalcet for at least 7 days prior to initiating Parsabiv®. Closely monitor corrected serum calcium in patients receiving Parsabiv® and concomitant therapies known to lower serum calcium.

Measure corrected serum calcium prior to initiation of Parsabiv®. Do not initiate in patients if the corrected serum calcium is less than the lower limit of normal. Monitor corrected serum calcium within 1 week after initiation or dose adjustment and every 4 weeks during treatment with Parsabiv®. Measure PTH 4 weeks after initiation or dose adjustment of Parsabiv®. Once the maintenance dose has been established, measure PTH per clinical practice.

Worsening Heart Failure: In Parsabiv® clinical studies, cases of hypotension, congestive heart failure, and decreased myocardial performance have been reported. Closely monitor patients treated with Parsabiv® for worsening signs and symptoms of heart failure.

Upper Gastrointestinal Bleeding: In clinical studies, 2 patients treated with Parsabiv® in 1253 patient years of exposure had upper gastrointestinal (GI) bleeding at the time of death. The exact cause of GI bleeding in these patients is unknown and there were too few cases to determine whether these cases were related to Parsabiv®.

Patients with risk factors for upper GI bleeding, such as known gastritis, esophagitis, ulcers or severe vomiting, may be at increased risk for GI bleeding with Parsabiv®. Monitor patients for worsening of common Parsabiv® GI adverse reactions and for signs and symptoms of GI bleeding and ulcerations during Parsabiv® therapy.

Adynamic Bone: Adynamic bone may develop if PTH levels are chronically suppressed.

Adverse Reactions: In clinical trials of patients with secondary HPT comparing Parsabiv® to placebo, the most common adverse reactions were blood calcium decreased (64% vs. 10%), muscle spasms (12% vs. 7%), diarrhea (11% vs. 9%), nausea (11% vs. 6%), vomiting (9% vs. 5%), headache (8% vs. 6%), hypocalcemia (7% vs. 0.2%), and paresthesia (6% vs. 1%).

Indication

Parsabiv® (etelcalcetide) is indicated for the treatment of secondary hyperparathyroidism (HPT) in adult patients with chronic kidney disease (CKD) on hemodialysis.

Limitations of Use: Parsabiv® has not been studied in adult patients with parathyroid carcinoma, primary hyperparathyroidism, or with CKD who are not on hemodialysis and is not recommended for use in these populations.

Please see Parsabiv® (etelcalcetide) full Prescribing Information.